Skip to main content

Tarceva Side Effects

Generic name: erlotinib

Medically reviewed by Philip Thornton, DipPharm. Last updated on Sep 29, 2022.

Note: This document contains side effect information about erlotinib. Some dosage forms listed on this page may not apply to the brand name Tarceva.

Applies to erlotinib: oral tablet.

Serious side effects of Tarceva

Along with its needed effects, erlotinib (the active ingredient contained in Tarceva) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking erlotinib:

More common

Rare

Incidence not known

Other side effects of Tarceva

Some side effects of erlotinib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common

Incidence not known

For Healthcare Professionals

Applies to erlotinib: oral tablet.

Respiratory

Very common (10% or more): Dyspnea (41%), cough (33%)

Common (1% to 10%): Epistaxis, interstitial lung disease[Ref]

Dermatologic

Very common (10% or more): Rash (75%), alopecia (14%), pruritus (13%), dry skin (12%)

Common (1% to 10%): Acne, dermatitis acneiform, folliculitis, skin fissures, paronychia

Uncommon (0.1% to 1%): Hyperpigmentation, hirsutism, brittle/loose nails, eyebrow changes

Rare (less than 0.1%): Palmar plantar erythrodysesthesia syndrome, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN)[Ref]

Gastrointestinal

Very common (10% or more): Diarrhea (54%), nausea (33%), vomiting (23%), stomatitis (22%), dyspepsia (17%), flatulence (13%), abdominal pain (11%)

Common (1% to 10%): GI bleeding

Uncommon (0.1% to 1%): GI perforations[Ref]

Hepatic

Common (1% to 10%): Liver function test abnormalities (including elevated ALT, AST, bilirubin)

Rare (less than 0.1%): Hepatic failure and hepatorenal syndrome (including fatalities)[Ref]

Immunologic

Very common (10% or more): Infections (24%)[Ref]

Ocular

Very common (10% or more): Keratoconjunctivitis sicca (12%), conjunctivitis (12%)

Common (1% to 10%): Keratitis

Uncommon (0.1% to 1%): Eyelash changes

Rare (less than 0.1%): Corneal ulcerations or perforations

Postmarketing reports: Uveitis[Ref]

Renal

Common (1% to 10%): Renal insufficiency

Uncommon (0.1% to 1%): Nephritis, proteinuria

Other

Very common (10% or more): Fatigue (73%), pyrexia (36%)[Ref]

Cardiovascular

Common (1% to 10%): Myocardial infarction/ischemia, cerebrovascular accident

Metabolic

Very common (10% or more): Anorexia (53%), weight decreased (39%)

Musculoskeletal

Very common (10% or more): Rigors (12%)

Postmarketing reports: Myopathy, including rhabdomyolysis, in combination with statin therapy

Nervous system

Very common (10% or more): Headache (15%), neuropathy (13%)

Psychiatric

Very common (10% or more): Depression (19%)

Frequently asked questions

References

1. Product Information. Tarceva (erlotinib). Genentech. 2004.

2. Liu V, White DA, Zakowski MF, et al. Pulmonary toxicity associated with erlotinib. Chest. 2007;132:1042-4.

3. Cuetara MS, Aguilar A, Martin L, Aspiroz C, Del Palacio A. Erlotinib associated with rosacea-like folliculitis and Malassezia sympodialis. Br J Dermatol. 2006;155:477-9.

4. PharmaLive. Skin rash actually signifies better outcomes for pancreatic and lung cancer patients. http://pharmalive.com/news/Print.cfm?articleid=456520 2007.

5. Marquez G, Herrera-Acosta E, Vidal I, Galvany L, Iglesias M, Umbert P. A case of trichomegaly of the eyelashes and facial hypertrichosis induced by erlotinib (Tarceva). Int J Dermatol. 2009;48:97-8.

6. Pellegrinotti M, Fimognari FL, Franco A, Repetto L, Pastorelli R. Erlotinib-induced hepatitis complicated by fatal lactic acidosis in an elderly man with lung cancer. Ann Pharmacother. 2009;43:542-5.

7. Lee SM, Buchler T, Joseph T, Lai C. Bilateral eardrum perforation after long-term treatment with erlotinib. J Clin Oncol. 2008;26:2582-4.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.